TCR2 Therapeutics Inc.
News
Kevin C. Tang Acquires 50,000 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock
Zolmax TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) major shareholder Kevin C. Tang bought 50,000 shares of the companys stock in a transaction on Thursday, May 25th. The stock was bought at an average price of $1.72 per share, for a total transaction of $86,000.00. Following the completion of the ...\n more…
Insider Selling: TCR2 Therapeutics Inc. (NASDAQ:TCRR) Major Shareholder Sells $131,919.60 in Stock
Ticker Report TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) major shareholder Mpm Asset Management Llc sold 70,170 shares of the companys stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $1.88, for a total transaction of $131,919.60. Following the sale, ...\n more…
Mpm Asset Management Llc Sells 70,170 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock
Zolmax TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) major shareholder Mpm Asset Management Llc sold 70,170 shares of the companys stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $1.88, for a total value of $131,919.60. Following the transaction, the ...\n more…
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Consensus Rating of "Hold" by Brokerages
Ticker Report TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) has earned a consensus rating of Hold from the eight ratings firms that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold rating and two have issued a buy rating on the company. ...\n more…
Analysts Set TCR2 Therapeutics Inc. (NASDAQ:TCRR) PT at $3.57
Zolmax TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) has received an average rating of Hold from the eight analysts that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the ...\n more…
TCR2 Therapeutics Inc. (NASDAQ:TCRR) Major Shareholder Kevin C. Tang Purchases 6,183 Shares
Zolmax TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) major shareholder Kevin C. Tang acquired 6,183 shares of the stock in a transaction on Friday, May 12th. The shares were acquired at an average price of $1.95 per share, with a total value of $12,056.85. Following the transaction, the insider now ...\n more…